Carterra Bio
1 known investors
Carterra develops surface plasmon resonance (SPR) platforms for high-throughput biomolecular interaction analysis. The systems are designed for drug discovery, antibody development, and screening applications in research and biotech organizations.
Investors Β· 1
Non-dilutive funding Β· 12 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $329.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $327.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2011 | $811.1K |
| National Science Foundation | Phase II | 2009 | $495.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2008 | $212.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $199.8K |
| National Science Foundation | Phase I | 2008 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Carterra Bio do?
- Carterra develops surface plasmon resonance (SPR) platforms for high-throughput biomolecular interaction analysis. The systems are designed for drug discovery, antibody development, and screening applications in research and biotech organizations.
- Who are Carterra Bio's investors?
- Carterra Bio's investors include Telegraph Hill Partners.